EPHA2 and triple-negative breast carcinoma: Indeed, EphA2 has been evaluated as a drug target using multiple approaches, such as agonist antibodies in leukemia (Charmsaz et al., 2015) and small molecule inhibitors in triple-negative breast cancer (Song et al., 2017).